Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMSZIP5)

Drug Name

SB-639 Drug Info

Synonyms

SB-639; CHEMBL491316; AC1OCG09; SCHEMBL13118363; BDBM50248476; US8551988, 72; N-hydroxy-3-(2-phenethyl-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol-5-yl)acrylamide; (E)-N-hydroxy-3-[2-phenethyl-1-(2-pyrrolidin-1-ylethyl)benzimidazol-5-yl]prop-2-enamide

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Therapeutic Class

Anticancer Agents

Cross-matching ID

PubChem CID: 6918877
TTD Drug ID: DMSZIP5

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histone deacetylase 1 (HDAC1)	TT6R7JZ	HDAC1_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Histone deacetylase 1 (HDAC1)	DTT	HDAC1	6.206	8.094	7.236	7.56

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Solid tumour/cancer

ICD Disease Classification

2A00-2F9Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Histone deacetylase 1 (HDAC1)	DTT	HDAC1	6.27E-01	0.11	0.33

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Epigenetics in vascular disease - therapeutic potential of new agents. Curr Vasc Pharmacol. 2014 Jan;12(1):77-86.
2	Histone deacetylase inhibitors in cancer therapy: latest developments, trends and medicinal chemistry perspective. Anticancer Agents Med Chem. 2007 Sep;7(5):576-92.